Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Ranibizumab
Related studies linked through entity extraction aliases.
Head to Head Study of Anti-VEGF Treatment.
- Status
- COMPLETED
- Phase
- PHASE4
Study of DS-7080a for the Treatment of Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE1
Retinal Sensitivity in BRVO After Anti-VEGF Therapy
- Status
- UNKNOWN
- Phase
- PHASE4
Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas
- Status
- UNKNOWN
- Phase
- PHASE4
Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
- Status
- WITHDRAWN
- Phase
- PHASE2
Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE2
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
- Status
- COMPLETED
- Phase
- PHASE2
Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion
- Status
- COMPLETED
- Phase
- PHASE4
A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE3
To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema
- Status
- UNKNOWN
- Phase
- PHASE4
25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial
- Status
- UNKNOWN
- Phase
- PHASE3
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
- Status
- TERMINATED
- Phase
- PHASE2
RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
- Status
- COMPLETED
- Phase
- PHASE3
Geographic Atrophy and Intravitreal Ranibizumab Injections
- Status
- UNKNOWN
- Phase
- N/A
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE2
Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema
- Status
- COMPLETED
- Phase
- N/A